aTyr Pharma, Inc. Common Stock
ATYRaTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies targeting rare and severe diseases, particularly those involving neuroinflammation and immune modulation. The company's approach involves designing molecules that can restore or maintain healthy cellular functions, with an emphasis on the nervous and immune systems.
Company News
Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.
aTyr Pharma's stock plummeted 83% after its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint, raising concerns about the drug's future development.
aTyr Pharma is developing efzofitimod, a potential treatment for pulmonary sarcoidosis, with promising phase 2 results and a significant target market of approximately 100,000 patients in the U.S. The company's upcoming phase 3 study results will be critical in determining its future success.
Here is how Atyr Pharma (ATYR) and High Tide Inc. (HITI) have performed compared to their sector so far this year.
